Please login to the form below

Not currently logged in
Email:
Password:

cabotegravir

This page shows the latest cabotegravir news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

ViiV chalks up another win for two-drug HIV regimen

After switching to the injectable regimen of integrase inhibitor cabotegravir and Johnson &Johnson’s non-nucleoside RTI rilpivirine, the patients showed similar efficacy after 48 weeks’treatment, with ViiV’s combination ... ViiV and J&J are also

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics